Jump to content

AstraZeneca lung cancer drug fails trial! Recentin New Drug!


Recommended Posts

AstraZeneca lung cancer drug fails trial

AstraZeneca has suffered a setback after it admitted today that its lung cancer treatment Recentin had failed a clinical trial designed to compare it with rival drug Avastin.

In a statement, Alan Barge of Astra’s oncology division said of the Phase II/III trial: "While we recognised that challenging Avastin would be a high hurdle, it is still disappointing, despite evidence of clinical activity with Recentin, not to have met the primary endpoint in this study."

AstraZeneca said it would persevere with other trials, includine one to assess Recentin combined with chemotherapy against chemotherapy alone; and another into the drug’s utility as a treatment for tumours.

The group said the setback would not affect its financial guidance for 2010.


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.